Acth

(corticotropin)

Phase 2Small molecule

IIstituto Clinico Humanitas

Acth is one of 40 small molecule programs targeting Septic Shock. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Infantile SpasmsActive, not recruiting

Septic ShockPreclinical

Active, not recruiting

Infantile SpasmsPhase 2

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Acth

IIstituto Clinico Humanitas

Phase 2

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Avastin

BBio-Thera Solutions

Preclinical

1 8

Tygacil

PPrism Pharmaceuticals

Preclinical

1 9

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infantile Spasms1 trial

Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004758·30 enrolled

Septic Shock1 trial

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00005890·56 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ACTH

NDA NDA008317

Jan 1, 1982

ACTHAR

NDA NDA007504

Jan 1, 1982

ACTHAR GEL

NDA NDA008372

Jan 1, 1982

CORTICOTROPIN

NDA NDA010831

Jan 1, 1982

PURIFIED CORTROPHIN GEL

NDA NDA008975

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for corticotropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — corticotropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for corticotropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA008317). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Acth. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIstituto Clinico Humanitas

Patent Landscape[5]

Patent Cliff

Jul 18, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11752199Jul 18, 2041

12440542Oct 27, 2043

12102662Oct 27, 2043

12233105Oct 27, 2043

11975047Oct 27, 2043

1 more patents

12324787Oct 27, 2043

Acth

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infantile Spasms1 trial

Septic Shock1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News